OakChart

GH Research PLC

GHRSHealthcare·Biotechnology·Ireland·Small·NASD·Nov 11 • 3:59 PM ET

19.25-0.31 (-1.58%)
2026-11-12 05:07 CET
Market cap
1,321.36 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-62.27 USD m
Free cash flow, TTM
-52.46 USD m
EPS diluted, TTM
-0.99
P/E
-
Compare

Price

GHRS against its 20, 50 and 200-day averages
2050200beatmiss
15.0020.0025.0030.00742K1.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GHRSclose 19.2520-day 19.4050-day 22.67200-day 21.6719.2552w high

38.8% under the 52-week high of 31.44 on 7 Aug 2026. 52-week low 12.04 on 16 Dec 2025. Last 15 sessions, 26.2% high to low

Volume 0.43× normal · the line is the 50-bar volume average

Profile

GHRS
52-week range, 37% of the way up
12.0431.44

GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Employees73
IPOJun 25, 2021
Beta1.33
ATR, 14d1.22
Rel volume0.43
Short float4.08%
Insider own25.83%
Inst own70.64%

Snapshot

6 groups

Valuation

Index-
Market Cap1.32B
Enterprise Value959.07M
Income-62.27M
Sales0.00M
Book/sh5.24
Cash/sh5.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees73
IPOJun 25, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.68
P/C3.64
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio28.70
Current Ratio28.70
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.99
EPS next Y-1.83
EPS next Q-0.31
EPS this Y-51.26%
EPS next Y-53.19%
EPS next 5Y-
EPS past 3/5Y-22.35% -162.03%
Sales past 3/5Y- -
EPS Y/Y TTM-33.76%
Sales Y/Y TTM-
EPS Q/Q-52.04%
Sales Q/Q-
EarningsAug 06 BMO
EPS/Sales Surpr.24.34% -

Ownership

Insider Own25.83%
Insider Trans0.00%
Inst Own70.64%
Inst Trans10.59%
ROA-18.16%
ROE-18.79%
ROIC-17.32%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.77%
SMA50-15.08%
SMA200-11.15%
Trades-

Technical

Shs Outstand68.64M
Shs Float50.91M
Short Float4.08%
Short Ratio6.96
Short Interest2.08M
52W High31.44 -38.77%
52W Low12.04 59.88%
Volatility5.55% 6.31%
ATR (14)1.22
RSI (14)42.23
Beta1.33
Rel Volume0.43
Avg Volume298.73K
Volume128,403

Performance

Perf Week-3.41%
Perf Month2.12%
Perf Quarter-31.71%
Perf Half Y-12.02%
Perf YTD51.57%
Perf Year35.37%
Perf 3Y134.47%
Perf 5Y-16.01%
Perf 10Y-
Recom1.00
Target Price41.70
Prev Close19.56
Price19.25
Change %-1.58%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Jul 27, 2026InitiatedWWells FargoOverweight$44+128.6%
Oct 13, 2025InitiatedNNeedhamBuy$19-1.3%
Jun 04, 2025ResumedCCantor FitzgeraldOverweight$25+29.9%
Mar 13, 2025InitiatedGGuggenheimBuy$32+66.2%
Mar 07, 2025InitiatedRRBC Capital MktsOutperform$31+61.0%
Feb 13, 2025InitiatedCCantor FitzgeraldOverweight$14-27.3%
Aug 16, 2022InitiatedHH.C. WainwrightBuy$45+133.8%
Jun 16, 2022InitiatedRROTH CapitalBuy$66+242.9%

Peers

Mkt cap
TickerCompanyMkt cap
DFTXDefinium Therapeutics Inc4.72B
CMPSCompass Pathways Plc ADR1.32B
AXSMAxsome Therapeutics Inc7.85B
PBMPsyence Biomedical Ltd12.13M
ACADAcadia Pharmaceuticals Inc3.17B
NMRANeumora Therapeutics Inc88.87M
CMNDClearmind Medicine Inc2.51M
SUPNSupernus Inc6.12B
JNJJohnson & Johnson675.03B
NBIXNeurocrine Biosciences Inc17.65B

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
PSILAdvisorShares Psychedelics ETFAUM: 43.26M
EIRLiShares MSCI Ireland ETFAUM: 79.51M
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M
FPXEFirst Trust IPOX (R) Europe Equity Opportunities ETFAUM: 4.75M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-06-0.230-0.304-0.2300.000.0010
2026Q12026-05-14-0.310-0.293-0.3060.000.009
2025Q42026-03-05-0.230-0.264-0.2280.000.009
2025Q32025-11-06-0.230-0.237-0.2260.000.009
2025Q22025-08-07-0.150-0.214-0.1500.000.008
2025Q12025-05-08-0.190-0.365-0.1860.000.008
2024Q42025-02-27-0.176-0.236-0.1690.000.007
2024Q32024-11-14-0.230-0.246-0.2330.000.005
2024Q22024-09-03-0.200-0.220-0.2000.000.001
2024Q12024-05-03-0.150-0.220-0.1470.000.005
2023Q42024-02-29-0.214-0.204-0.2170.000.005
2023Q32023-11-09-0.110-0.200-0.1090.000.005
2023Q22023-08-23-0.150-0.210-0.1490.000.002
2023Q12023-05-11-0.210-0.216-0.2100.000.005
2022Q42023-03-02-0.290-0.168-0.3190.000.006
2022Q32022-11-10-0.008-0.163-0.0090.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-0.211-0.308-0.1770.000.00
2022FY-0.432-0.283-0.4320.000.00
2023FY-0.680-0.674-0.6840.000.00
2024FY-0.750-0.810-0.7490.000.00
2025FY-0.787-0.844-0.7880.000.00
2026FY--1.195--0.00
2027FY--1.831--0.00
2028FY--1.989--3.90
2029FY--1.310--115.91
2030FY--0.115--344.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-068000.000.000.00
2026Q3S2026-07-248000.000.000.00
2026Q3S2026-07-157000.000.000.00
2026Q3S2026-06-146000.000.000.00
2026Q3S2026-05-147000.000.000.00
2026Q3S2026-03-067000.000.000.00
2026Q3S2026-03-056000.000.000.00
2026Q3S2026-03-046000.000.000.00
2026Q3S2026-01-305000.000.000.00
2026Q3S2025-11-114000.000.000.00
2026Q3S2025-11-104000.000.000.00
2026Q3S2025-11-094000.000.000.00
2026Q3S2025-11-084000.000.000.00
2026Q3S2025-11-074000.000.000.00

Estimate history

EPS, annual-0.004-0.006-0.177-0.432-0.684-0.749-0.791-0.9873
Period2019202020212022202320242025TTM
EPS, quarterly-0.2-0.233-0.169-0.186-0.15-0.226-0.228-0.306-0.228
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual707052.02152.02152.02852.02862.02968.642
Period2019202020212022202320242025MRQ
Shares, quarterly52.02152.02852.02862.02862.02962.02962.02962.05368.642
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.360.340.320.320.050.020.000.00
Gross Profit-0.36-0.34-0.32-0.32-0.05-0.020.000.00
Selling, General and Administrative Excl. Other71.0760.3449.9340.9130.5115.080.450.31
Research and Development46.7138.7335.0029.7920.458.550.340.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-71.43-60.68-50.25-41.22-30.55-15.10-0.45-0.31
Interest Expense0.280.460.720.720.000.000.000.00
Unusual Expense-8.27-8.50-7.25-7.090.000.000.000.00
Net Income Before Taxes-62.27-48.26-38.96-35.59-22.46-9.20-0.45-0.31
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-62.27-48.26-38.96-35.59-22.46-9.20-0.45-0.31
Net Income From Continuing Operations-62.27-48.26-38.96-35.59-22.46-9.20-0.45-0.31
Net Income-62.27-48.26-38.96-35.59-22.46-9.20-0.45-0.31
EPS (Recurring)-1.02-0.89-0.85-0.78-0.43-0.18-0.01-0.00
EPS (Basic, Before Extraordinaries)-0.99-0.79-0.75-0.68-0.43-0.18-0.01-0.00
EPS (Diluted)-0.99-0.79-0.75-0.68-0.43-0.18-0.01-0.00
EBITDA-71.07-60.34-49.93-40.91-30.51-15.08-0.45-0.31
Non-Operating Income (Expense)1.174.384.76-0.738.105.900.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.908.501.172.291.670.37--
Shares Outstanding68.6462.0352.0352.0352.0252.0270.0070.00
Market Capitalization1,321.361,321.36364.20301.72505.641,213.651,154.34-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.090.090.090.090.080.080.080.08
Gross Profit-0.09-0.09-0.09-0.09-0.08-0.08-0.08-0.08
Selling, General and Administrative Excl. Other19.3618.6616.6116.4514.6112.6812.8512.54
Research and Development12.4012.3811.3810.568.957.858.208.39
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.45-18.75-16.70-16.54-14.69-12.75-12.92-12.62
Interest Expense0.080.080.090.020.170.180.180.18
Unusual Expense-1.85-1.86-2.16-2.40-2.48-1.47-1.13-1.97
Net Income Before Taxes-15.15-18.97-14.14-14.02-9.29-10.81-8.80-12.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-15.15-18.97-14.14-14.02-9.29-10.81-8.80-12.11
Net Income From Continuing Operations-15.15-18.97-14.14-14.02-9.29-10.81-8.80-12.11
Net Income-15.15-18.97-14.14-14.02-9.29-10.81-8.80-12.11
EPS (Recurring)-0.25-0.33-0.25-0.25-0.18-0.20-0.18-0.26
EPS (Basic, Before Extraordinaries)-0.23-0.31-0.23-0.23-0.15-0.19-0.17-0.23
EPS (Diluted)-0.23-0.31-0.23-0.23-0.15-0.19-0.17-0.23
EBITDA-19.36-18.66-16.61-16.45-14.61-12.68-12.85-12.54
Non-Operating Income (Expense)2.54-2.000.490.143.100.653.17-1.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.201.802.602.301.800.700.770.10
Shares Outstanding68.6462.0562.0362.0362.0362.0352.0352.03
Market Capitalization1,321.36872.13787.77887.00756.12684.17364.20348.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments280.71149.32161.56165.96276.785.900.50
Short Term Receivables1.301.730.180.090.050.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets3.973.172.352.503.020.020.01
Total Current Assets285.98154.23164.09168.54279.845.910.50
Net Property, Plant & Equipment0.620.751.070.100.080.000.00
Total Investments and Advances0.0033.3061.1485.720.000.000.00
Intangible Assets-0.000.000.000.000.000.00
Other Assets1.630.000.000.000.000.000.00
Total Assets288.23188.27226.30254.36279.925.910.50
Short Term Debt Incl. Current Port. of LT Debt0.370.260.340.000.000.000.00
Accounts Payable0.000.000.000.000.000.000.00
Other Current Liabilities8.028.706.364.552.750.250.10
Total Current Liabilities8.388.956.704.552.750.250.10
Long Term Debt0.150.370.630.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities8.539.327.334.552.750.250.10
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.070.00
Common Equity279.70178.95218.97249.82277.185.600.40
Total Shareholders Equity279.70178.95218.97249.82277.185.670.40
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity279.70178.95218.97249.82277.185.670.40
Total Liabilities & Stockholders Equity288.23188.27226.30254.36279.925.910.50
Book Value Per Share4.513.444.214.805.330.080.01
Tangible Book Value Per Share4.513.444.214.805.330.080.01
Full-Time Employees73504932148-
Price to Book Ratio3.681.921.341.974.384.07-
Return on Assets-20.26-18.80-14.81-8.41-6.44-13.90-
Return on Equity-21.04-19.58-15.18-8.52-6.51-14.70-
Return on Invested Capital-17.24-21.73-16.21-8.99-3.32-7.87-77.50
Quick Ratio34.1317.2324.4937.07101.8024.034.85
Current Ratio34.1317.2324.4937.07101.8024.034.85

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-62.91-48.26-38.96-35.59-22.46-9.20-0.45-0.31
Depreciation0.360.340.320.320.050.02--
Other Funds (Non Cash)12.737.47-3.830.29-5.95-5.540.000.00
Funds from Operations-49.82-40.46-42.47-34.98-28.36-14.72-0.45-0.31
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.50-3.090.191.652.16-0.560.120.02
Cash from Operating Activities-52.32-43.55-42.29-33.34-26.20-15.28-0.33-0.29
Capital Expenditures-0.14-0.12-0.05-0.10-0.07-0.100.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments54.4346.2965.18-54.00-84.620.000.000.00
Purchase of Investments0.000.000.00-54.00-84.620.000.000.00
Sale Or Maturity of Investments54.4346.2965.180.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources-20.330.000.000.000.000.000.000.00
Cash from Investing Activities33.9646.1765.14-54.10-84.69-0.100.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock110.74139.850.000.020.00286.455.500.80
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock110.74139.850.000.020.00286.455.500.80
Proceedsfrom Stock Options110.74139.850.000.020.00286.455.500.80
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities110.47139.65-0.30-0.200.00286.455.500.80
Exchange Rate Effect-2.473.19-0.180.110.07-0.180.23-0.01
Net Change in Cash89.63145.4622.37-87.54-110.82270.885.400.50
Free Cash Flow-52.46-43.67-42.33-33.44-26.27-15.39-0.33-0.29
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments362.65267.33280.71288.51291.54291.35
Short Term Receivables0.000.001.300.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets6.174.913.976.282.353.32
Total Current Assets368.82272.23285.98294.79293.88294.67
Net Property, Plant & Equipment0.500.580.620.690.740.71
Total Investments and Advances0.000.000.005.3817.1523.99
Other Assets3.022.461.631.161.661.09
Total Assets372.35275.27288.23302.02313.43320.45
Short Term Debt Incl. Current Port. of LT Debt0.350.360.370.370.360.34
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities12.5011.468.0210.049.609.58
Total Current Liabilities12.8511.828.3810.419.979.92
Long Term Debt0.010.080.150.220.280.32
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities12.8611.898.5310.6310.2510.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity359.49263.38279.70291.40303.18310.21
Total Shareholders Equity359.49263.38279.70291.40303.18310.21
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity359.49263.38279.70291.40303.18310.21
Total Liabilities & Stockholders Equity372.35275.27288.23302.02313.43320.45
Book Value Per Share5.244.244.514.704.895.00
Tangible Book Value Per Share5.244.244.514.704.895.00
Full-Time Employees--73---
Price to Book Ratio3.683.122.702.932.443.21
Return on Assets-18.16-18.94-20.26-17.11-15.76-15.65
Return on Equity-18.79-19.67-21.04-17.86-16.35-16.20
Return on Invested Capital-4.21-7.20-5.05-4.81-3.06-3.48
Quick Ratio28.7023.0434.1328.3229.4929.71
Current Ratio28.7023.0434.1328.3229.4929.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-15.04-18.97-14.08-14.83-10.05-10.81
Depreciation0.090.090.090.090.090.08
Other Funds (Non Cash)0.865.253.323.30-0.881.95
Funds from Operations-14.09-13.63-10.67-11.43-10.84-8.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.852.96-1.59-3.021.210.21
Cash from Operating Activities-14.94-10.67-12.26-14.46-9.63-8.57
Capital Expenditures-0.02-0.06-0.02-0.04-0.06-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments6.318.7029.0710.343.494.84
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments6.318.7029.0710.343.494.84
Other Uses0.000.000.000.000.000.00
Other Sources0.000.00-20.490.1613.337.00
Cash from Investing Activities6.308.648.5710.4616.7511.84
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock111.580.07-2.061.164.27140.86
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock111.580.07-2.061.164.27140.86
Proceedsfrom Stock Options111.580.07-2.061.164.27140.86
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities111.510.00-2.131.094.21140.86
Exchange Rate Effect-0.78-1.570.12-0.243.370.04
Net Change in Cash102.08-3.60-5.71-3.1414.70144.16
Free Cash Flow-14.96-10.73-12.27-14.50-9.69-8.58

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.08%2.1M50.9M296.24K
2026-10-153.95%2.0M50.9M302.40K
2026-09-303.46%1.8M50.9M286.32K
2026-09-155.31%2.7M50.9M275.99K
2026-08-316.06%3.1M50.9M285.41K
2026-08-146.19%3.1M50.8M306.26K
2026-07-314.97%2.5M50.9M261.25K
2026-07-153.82%1.9M50.9M264.17K
2026-06-303.81%1.9M50.9M249.72K
2026-06-153.98%2.0M50.9M229.81K
2026-05-294.49%2.2M49.0M234.04K
2026-05-154.27%2.1M49.0M215.46K
2026-04-304.35%2.1M49.4M222.64K
2026-04-154.81%2.2M44.7M196.60K
2026-03-314.94%2.2M44.9M369.28K
2026-03-135.82%2.6M44.9M382.70K
2026-02-276.03%2.7M44.9M367.02K
2026-02-136.79%3.0M44.9M387.98K
2026-01-306.58%3.0M44.9M440.99K
2026-01-155.67%2.5M44.9M438.45K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10.007.8011.5010.186.8301.000.000.874-0.2490.006
call12.505.009.000.005.1820.000.000.825-0.2360.008
call15.002.506.500.003.8520.000.000.762-0.2120.009
call17.500.104.900.003.5140.000.000.670-0.1770.011
call20.000.004.901.154.4031.000.000.607-0.2750.012
call22.500.004.900.705.06769.000.000.578-0.3370.012
call25.000.001.400.104.0081.000.000.483-0.2620.013
call30.000.004.901.403.3991.000.000.283-0.1960.010
call35.000.004.900.003.9880.000.000.257-0.2180.010
call40.000.004.900.004.4650.000.000.241-0.2360.009
put10.000.004.900.007.0420.000.00-0.124-0.2430.006
put12.500.004.900.005.4230.000.00-0.168-0.2320.008
put15.000.004.900.004.0950.000.00-0.227-0.2100.009
put17.500.002.400.932.8371.000.00-0.330-0.1750.011
put20.000.004.900.003.7710.000.00-0.393-0.2730.012
put22.501.005.401.802.77210.000.00-0.422-0.3340.012
put25.003.508.000.003.3930.000.00-0.668-0.1590.011
put30.008.5012.700.003.9460.000.00-0.717-0.1920.010
put35.0013.5017.800.004.6570.000.00-0.743-0.2150.010
put40.0018.5022.800.005.1590.000.00-0.759-0.2320.009

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-10-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-09SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-26SEC
2026-06-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-04SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-21SEC
2026-05-19EFFECTEffectiveness filing by commission orderSEC
2026-05-18SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-14F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-05-14424B5SEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-29424B5SEC
2026-04-173Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Lynx1 Capital Management LP19.35%
BVF INC/IL12.62%
RA CAPITAL MANAGEMENT, L.P.11.14%
FMR LLC9.44%
RTW INVESTMENTS, LP8.66%
Deep Track Capital, LP4.86%
Avoro Capital Advisors LLC2.63%
Foresite Capital Management VI LLC1.37%
BlackRock, Inc.0.70%
Jefferies Financial Group Inc.0.53%

Funds

Fund% owned
Fidelity Growth Company Fund2.82%
Fidelity Growth Company K6 Fund0.91%
Fidelity Series Growth Company Fund0.71%
iShares Biotechnology ETF0.50%
Select Biotechnology Portfolio0.26%
AdvisorShares Psychedelics ETF0.10%
iShares MSCI Ireland ETF0.08%
Fidelity Nasdaq Composite Index Fund0.06%
Virtus Biotech Clinical Trials Etf0.02%
BNY Mellon Small Cap Multi-Strategy Fund0.02%

OakChart. GHRS. Cached 15 minutes.

Some panels did not load: insider.